A Prognostic Cuproptosis-Related LncRNA Signature for Colon Adenocarcinoma

Figure 9

Drug sensitivities as a function of the risk group for (a) bicalutamide, (b) gefitinib, (c) GSK.650394, (d) lenalidomide, (e) nilotinib, (f) rapamycin, (g) salubrinal, (h) shikonin, (i) tipifarnib, and (j) vinblastine.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)